Intranasal (IN) Research Summary
Semax has been studied extensively via the intranasal route in human clinical and preclinical settings. The following bullets summarize reported findings from the literature. All stated amounts are reported in studies unless otherwise noted.
- Primary studied route: Intranasal delivery (nasal drops or spray) is the predominant preparation route in published human research for Semax; oral bioavailability is poor due to rapid enzymatic degradation[1][14]. (Reported in studies.)
- Approved formulation (Russia): Semax is registered as a 0.1% intranasal solution (equivalent to 1,000 mcg/mL or 1.0 mg/mL) dispensed via dropper bottle; each standard drop is reported to deliver approximately 50 mcg of peptide[2]. (Reported in studies.)
- Higher‑concentration formulation: A 1% Semax intranasal solution (10,000 mcg/mL or 10.0 mg/mL) has been used in acute neurological settings (e.g., ischemic stroke) to deliver larger amounts per actuation without excessive volume[3][2]. (Reported in studies.)
- Delivery device: Published clinical protocols describe a dropper bottle with a cap‑pipette; some formulations reference a metered nasal spray. Specific per‑actuation delivered volume for spray devices was not consistently reported across studies[2][11]. (Reported in studies; device output not standardized across sources.)
- Cognitive/neuroprotective studies (human): In adult cerebrovascular research samples, total daily intranasal amounts of 200–6,000 mcg (divided into 3–4 administrations) were reported over courses of 5–14 days, with lower ranges (200–900 mcg/day) used for milder cognitive indications over shorter durations[2][3]. (Reported in studies.)
- Pediatric study (human): In children ages 7–18 with minimal brain dysfunction, daily intranasal amounts of 200–400 mcg (approximately 5–6 mcg/kg) divided into two administrations were reported over a 30‑day course[2]. (Reported in studies.)
- Optic neuropathy study (human): In 36 research samples with glaucomatous optic neuropathy, daily intranasal Semax was prepared for approximately one month; no significant adverse effects were reported[6]. (Reported in studies.)
- Pharmacokinetic notes: Intranasal Semax is reported to have a short duration of action, necessitating multiple daily administrations in clinical protocols. Preclinical comparison of intranasal versus measurement routes showed differences in onset and duration profiles, with measurement providing more sustained systemic levels[4][5]. (Reported in studies.)
- Variability and limitations: Intranasal bioavailability is subject to individual anatomical variation, mucosal condition, and device‑specific delivery volumes. Most published human data originate from Russian clinical registries and journals; large‑scale Western randomized controlled trials are lacking[14][12]. (Inference based on available evidence.)
Nasal Spray Device Output & Conversion Math
Important: Nasal spray pumps vary significantly in delivered volume per actuation depending on manufacturer, pump mechanism, and priming. The mcg delivered per spray depends entirely on the specific device used. Always use manufacturer specifications or direct gravimetric measurement to determine delivered volume per actuation.
Parameterized Framework
Given two known inputs, the amount per actuation can be calculated:
- Input 1:
concentration_mcg_per_mL(or convert from mg/mL × 1,000) - Input 2:
pump_output_mL_per_actuation(from device specs or measurement) - Output:
amount_mcg_per_actuation= concentration_mcg_per_mL × pump_output_mL_per_actuation
Optional volume mapping (U‑100 convention): If a “units” convention is used as a volume measure, 100 units = 1.0 mL. Therefore: pump_output_mL_per_actuation = units_per_actuation ÷ 100, and amount_mcg_per_actuation = concentration_mcg_per_mL × (units_per_actuation ÷ 100).
Nasal Actuation Calculation Table (Placeholders)
| Concentration (mcg/mL) | Pump Output (mL/actuation) | Amount per Actuation (mcg) | Actuations per mL (1 ÷ pump output) | Total Actuations in Reconstituted Volume |
|---|---|---|---|---|
| 1,667 | 0.10 | 166.7 | 10.0 | 30.0 (3.0 mL × 10) |
| 1,667 | 0.13 | 216.7 | 7.7 | 23.1 (3.0 mL × 7.7) |
| 2,500 | 0.10 | 250.0 | 10.0 | 20.0 (2.0 mL × 10) |
| 2,500 | 0.13 | 325.0 | 7.7 | 15.4 (2.0 mL × 7.7) |
Note: Concentrations above correspond to 5 mg reconstituted in 3.0 mL (1,667 mcg/mL) or 2.0 mL (2,500 mcg/mL). Pump output values are common placeholder ranges — verify with your specific device.
Worked Examples (Placeholders Only)
Example 1 (mL‑based): If concentration = 1,667 mcg/mL and pump output = 0.10 mL/actuation, then amount per actuation = 1,667 × 0.10 = 166.7 mcg.
Example 2 (units‑based): If concentration = 1,667 mcg/mL and pump output = 13 units/actuation, then pump output in mL = 13 ÷ 100 = 0.13 mL, and amount per actuation = 1,667 × 0.13 = 216.7 mcg.
How This Works
Semax is a stabilized synthetic analog of the adrenocorticotropic hormone fragment ACTH(4–10), designed to resist enzymatic degradation and enhance central nervous system bioavailability[5][11]. Preclinical and clinical research indicates that Semax modulates BDNF expression, supports neuronal survival, and influences monoaminergic neurotransmission[1]. In human studies, Semax has demonstrated cognitive‑enhancing effects in research samples with cerebrovascular conditions and minimal brain dysfunction, with courses typically lasting 10–30 days at daily intranasal doses of 200–6,000 mcg depending on severity[2][3]. When prepared, systemic absorption is more sustained compared to the intranasal route, potentially allowing once‑example calculation[4].